Hantz Financial Services Inc. Cuts Stock Position in ResMed Inc. (NYSE:RMD)

Hantz Financial Services Inc. lessened its stake in shares of ResMed Inc. (NYSE:RMD) by 2.5% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 44,134 shares of the medical equipment provider’s stock after selling 1,134 shares during the period. Hantz Financial Services Inc.’s holdings in ResMed were worth $10,093,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in the stock. True Wealth Design LLC increased its position in shares of ResMed by 2,200.0% during the third quarter. True Wealth Design LLC now owns 115 shares of the medical equipment provider’s stock valued at $28,000 after acquiring an additional 110 shares in the last quarter. Ashton Thomas Securities LLC purchased a new stake in ResMed during the 3rd quarter valued at $34,000. Rosenberg Matthew Hamilton bought a new stake in shares of ResMed in the 4th quarter worth $54,000. Capital Performance Advisors LLP purchased a new position in shares of ResMed in the third quarter worth $60,000. Finally, Quarry LP raised its stake in shares of ResMed by 271.9% in the second quarter. Quarry LP now owns 331 shares of the medical equipment provider’s stock worth $63,000 after purchasing an additional 242 shares during the last quarter. Hedge funds and other institutional investors own 54.98% of the company’s stock.

Insider Activity at ResMed

In other news, Director Witte Jan De sold 796 shares of the business’s stock in a transaction dated Tuesday, November 12th. The stock was sold at an average price of $248.81, for a total value of $198,052.76. Following the transaction, the director now directly owns 6,723 shares in the company, valued at $1,672,749.63. The trade was a 10.59 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Peter C. Farrell sold 2,000 shares of the stock in a transaction dated Wednesday, November 6th. The stock was sold at an average price of $248.74, for a total value of $497,480.00. Following the sale, the director now owns 83,204 shares of the company’s stock, valued at $20,696,162.96. This represents a 2.35 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 11,099 shares of company stock worth $2,719,385. 0.71% of the stock is owned by company insiders.

ResMed Stock Performance

NYSE:RMD opened at $249.25 on Wednesday. The stock has a 50-day simple moving average of $239.80 and a two-hundred day simple moving average of $235.71. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.91 and a current ratio of 2.92. ResMed Inc. has a 52-week low of $170.56 and a 52-week high of $260.49. The firm has a market capitalization of $36.59 billion, a PE ratio of 33.27, a P/E/G ratio of 1.78 and a beta of 0.70.

Wall Street Analyst Weigh In

RMD has been the subject of several research analyst reports. Robert W. Baird lifted their price objective on ResMed from $280.00 to $283.00 and gave the stock an “outperform” rating in a report on Friday, October 25th. The Goldman Sachs Group started coverage on shares of ResMed in a research note on Thursday, January 16th. They issued a “buy” rating for the company. KeyCorp increased their price objective on shares of ResMed from $251.00 to $266.00 and gave the company an “overweight” rating in a research report on Friday, October 25th. StockNews.com raised shares of ResMed from a “hold” rating to a “buy” rating in a research report on Tuesday, October 15th. Finally, Needham & Company LLC reissued a “hold” rating on shares of ResMed in a report on Friday, October 25th. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, ResMed has a consensus rating of “Moderate Buy” and an average price target of $238.40.

About ResMed

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights.